Last updated: April 24, 2026
Who Supplies Norpramin (Desipramine) for Pharmaceutical Use?
Norpramin is the brand name for desipramine. No global, definitive “supplier list” can be produced from the information provided. A complete supplier map depends on jurisdiction (product market authorization), dosage form, strength, and whether the question targets finished-dose distributors (finished product) or API manufacturers (desipramine active pharmaceutical ingredient).
What Counts as a “Supplier” for Norpramin?
- Finished-dose supply: companies that market and distribute the finished Norpramin product under local regulatory approvals.
- API supply: companies that manufacture desipramine (the active pharmaceutical ingredient) used by branded or generic manufacturers.
Finished-Dose Suppliers: What Determines Availability?
Norpramin supply is country-specific because authorization, labeling, and distribution rights differ by market. In practice, finished-dose “suppliers” usually resolve to:
- the marketing authorization holder (MAH) in that country, and
- the local wholesaler/distributor network tied to that MAH.
API Suppliers: What Determines the API Supply Chain?
API supplier lists also depend on:
- the grade (e.g., pharma-grade specification),
- DMF/CEP linkage to registered dossiers in target markets, and
- intended formulation (tablets/capsules), since buyers often qualify API to specific regulatory filings.
Norpramin Supply Summary (Actionable Classification)
Because a complete supplier roster requires jurisdiction and product form, the only reliable way to structure supplier sourcing for Norpramin/desipramine is to split it into these two procurement tracks:
| Procurement track |
What you buy |
Supplier category |
Typical due diligence |
| Finished-dose |
Norpramin tablets/capsules (country-specific) |
MAH + local distributors |
Product registration, label/packaging, GDP chain |
| API |
Desipramine (API) |
API manufacturer + possible broker |
DMF/CEP status, CoA, impurity profile, regulatory status |
How to Build a Real Supplier List (Without Guesswork)
A defensible supplier list for business use is built by pulling the MAH and distributor network from regulatory and commercial sources, then confirming API qualification through:
- DMF/CEP identifiers referenced by finished-dose filings, and
- CoA and impurity limits aligned to pharmacopoeial and internal spec requirements.
Key Takeaways
- Norpramin is brand desipramine, so “suppliers for Norpramin” must be interpreted as either finished-dose distributors or API suppliers.
- Supplier identification is market- and form-specific. A universal supplier list cannot be stated without country and dosage form mapping.
- The most reliable approach is to enumerate (1) MAH/distributors per jurisdiction and (2) qualified desipramine API manufacturers tied to regulatory filings.
FAQs
-
Is Norpramin a branded product or an API?
Norpramin is a brand name for the finished pharmaceutical containing desipramine. Desipramine is the API.
-
Can I source Norpramin directly from an API manufacturer?
Usually no for finished-dose needs. API makers supply desipramine, while finished Norpramin is supplied by MAHs and distributors in each market.
-
Why do supplier lists differ by country?
Regulatory approvals and distribution rights are jurisdiction-specific, so MAHs and distributors differ.
-
What documents matter for qualifying an API supplier of desipramine?
Qualification typically relies on DMF/CEP linkage, impurity profile data, and CoA aligned to regulatory and pharmacopoeial specs.
-
What is the fastest route to confirm a legitimate source?
Use the market authorization holder/distributor chain for finished Norpramin, and tie any API sourcing to registered dossier references (DMF/CEP) for the target markets.
References
[1] DrugBank. “Desipramine.” https://go.drugbank.com/
[2] EMA. European public assessment reports and related regulatory information for desipramine products. https://www.ema.europa.eu/
[3] FDA. Drug approvals and prescribing information databases (US context where applicable). https://www.accessdata.fda.gov/
